Cellestia treatment in metastatic clear-cell renal cell carcinoma shows promising results

Monday, May 15, 2023 @ 12:00 am

In a recent study by Bui et al., titled “Metastatic clear-cell renal cell carcinoma: a frequent NOTCH1 mutation predictive of response to anti-NOTCH1 CB-103 treatment” the authors have shown that CB-103 eliminates NOTCH mutated clones, induces necrosis, exhibits anti-angiogenic activity, and thereby inhibits tumor growth in PDX models of metastatic ccRCC.

Metastatic clear cell renal cell carcinoma remains a high unmet medical need, as almost all patients develop resistance to the standard of care. Whole-genome sequencing (WGS) has identified a prevalence of activating mutations in NOTCH1 in metastatic ccRCCs. This independent study supports the clinical development of CB-103 in metastatic clear cell renal cell carcinoma.

Keep browsing

You may also be interested in

Featured

Swiss Biotech Association appoints Nicolas Durand as CEO and Odile Rundquist as Chief Strategy & Growth Officer

The Swiss Biotech Association has appointed Nicolas Durand as CEO, effective January 1, 2027, and Odile Rundquist as Chief Strategy & Growth Officer, as of December 1, 2026. Nicolas Durand will assume overall executive responsibility for the association, while Odile Rundquist will focus on strategic development, partnerships, and access to capital. The association’s priorities remain unchang
November 9, 2026

abc biopply and Panome Bio collaborate

abc biopply AG, Europe's fully integrated Organoid CRO, and Panome Bio, a leading US multi-omics CRO specializing in Next-Generation Metabolomics and integrated multi-omics analysis, today announced the signing of a strategic collaboration agreement aimed at expanding the availability of standardized, human-relevant preclinical data generation and advanced molecular analytics for pharmaceutical an
November 5, 2026

Mabylon reveals new allergy antibody mechanism

Peer-Reviewed Publication in Clinical & Experimental Allergy Reveals Potential Disease-Modifying Effect of Mabylon’s Allergen-Neutralizing Antibodies Allergen-specific, human-derived IgG4 antibodies prevent allergic reactions by neutralizing allergens and redirecting them toward tolerance-associated immune pathways. Mechanism-of-action observed across different allergy indications. Study pro
November 3, 2026

DEBRA Research invests in Topadur

Preclinical program will evaluate Topadur’s locally acting compounds, including clinical-stage TOP-N53, in dystrophic epidermolysis bullosa Studies in collaboration with the Medical Center – University of Freiburg and the EB Research Institute in Salzburg
October 28, 2026

Nouscom raises EUR 120 million in financing

Oversubscribed €120 million Series D financing was led by M Ventures and Revelation Partners, with new investors Angelini Industries, the European Investment Bank and Neva SGR and participation from all existing investors. Proceeds will fund advancement of Nouscom’s lead asset NOUS-209, an investigational, off-the-shelf neoantigen-based cancer immunotherapy, through a global, registration-enab
October 19, 2026

Newron flash update - Jumping the FDA hurdles should be manageable

October 11, 2026